CSF Levels of the Endocannabinoid Anandamide are Reduced in Patients with Untreated Narcolepsy Type 1: A Pilot Study

Andrea Romigi, Monica Bari, Claudio Liguori, Francesca Izzi, Cinzia Rapino, Marzia Nuccetelli, Natalia Battista, Sergio Bernardini, Diego Centonze, Nicola Biagio Mercuri, Fabio Placidi, Mauro Maccarrone

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Endocannabinoids (ECs) modulate both excitatory and inhibitory components in the CNS. There is a growing body of evidence that shows ECs influence both hypothalamic orexinergic and histaminergic neurons involved in narcolepsy physiopathology. Therefore, ECs may influence sleep and sleep-wake cycle.

OBJECTIVE: To evaluate EC levels in the CSF of untreated narcoleptic patients to test whether ECs are dysregulated in Narcolepsy Type 1 (NT1) and Type 2 (NT2).

METHODS: We compared CSF Anandamide (AEA), 2-Arachidonoylglycerol (2-AG) and orexin in narcoleptic drug-naïve patients and in a sample of healthy subjects.

RESULTS: We compared NT1 (n=6), NT2 (n=6), and healthy controls (n=6). We found significantly reduced AEA levels in NT1 patients compared to both NT2 and controls. No differences were found between AEA levels in NT2 versus controls and between 2-AG levels in all groups, although a trend toward a decrease in NT1 was evident. Finally, the CSF AEA level was related to CSF orexin levels in all subjects.

CONCLUSION: We demonstrated that the EC system is dysregulated in NT1.

Original languageEnglish
Pages (from-to)142-147
Number of pages6
JournalCNS and Neurological Disorders - Drug Targets
Volume19
Issue number2
DOIs
Publication statusPublished - 2020

Fingerprint Dive into the research topics of 'CSF Levels of the Endocannabinoid Anandamide are Reduced in Patients with Untreated Narcolepsy Type 1: A Pilot Study'. Together they form a unique fingerprint.

  • Cite this

    Romigi, A., Bari, M., Liguori, C., Izzi, F., Rapino, C., Nuccetelli, M., Battista, N., Bernardini, S., Centonze, D., Mercuri, N. B., Placidi, F., & Maccarrone, M. (2020). CSF Levels of the Endocannabinoid Anandamide are Reduced in Patients with Untreated Narcolepsy Type 1: A Pilot Study. CNS and Neurological Disorders - Drug Targets, 19(2), 142-147. https://doi.org/10.2174/1871527319666200309115602